Fighting the enemy properly?

Critical Care Medicine

Volumn 32, Issue 5, 2004, Pages 1223-1224

  Gibot, Sebastien ^a  

^a UNIVERSITY HOSPITAL OF NANCY   (France)

Author keywords

CD14 antibody; Innate immune system; Septic shock

Indexed keywords

CD14 ANTIGEN;

ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; EDITORIAL; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNITY; INFLAMMATORY CELL; INTENSIVE CARE; PRIORITY JOURNAL; SEPTIC SHOCK;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD4; CLINICAL TRIALS, PHASE I; DISEASE MODELS, ANIMAL; HUMANS; INFLAMMATION; RESEARCH DESIGN; SHOCK, SEPTIC; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 2442437890     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000125515.37781.9D     Document Type: Editorial

References (15)

1. Aderem A, Ulevitch RJ: Toll-like receptors in the induction of the innate immune response. Nature 2000; 406:782-786
2. Medzhitov R, Janeway C Jr: Innate immunity. N Engl J Med 2000; 343:338-344
3. Pugin J, Heermann D, Tomasz A: CD14 is a pattern recognition receptor. Immunity 1994; 1:509-516
4. Pugin J, Ulevitch RJ, Tobias PS: A critical role for monocytes and CD14 in endotoxin-induced endothelial cell activation. J Exp Med 1993; 178:2193-2200
5. Dziarski R, Tapping RI, Tobias PS: Binding of bacterial peptidoglycan to CD14. J Biol Chem 1998; 273:8680-8690
6. Ulevitch RJ: Toll gates for pathogen selection. Nature 1999; 401:455-456
7. Landmann R, Reben AM, Sansano S, et al: Function of soluble CD14 in serum from patients with septic shock. J Infect Dis 1996; 173:661-668
8. Landmann R, Zimmerli W, Sansano S, et al: Increased circulating soluble CD14 is associated with high mortality in Gram-negative septic shock. J Infect Dis 1995; 171:639-644
9. Burgmann H, Winkler S, Locker GJ, et al: Increased serum concentration of soluble CD14 is a prognostic marker in Gram-positive sepsis. Clin Immunol Immunopathol 1996; 80:307-310
10. Furusako S, Takahashi S, Mori Y, et al: Protection of mice from LPS-induced shock by CD14 antisense oligonucleotide. Acta Med Okoyama 2001; 55:105-115
11. Leturcq DJ, Moriarty AM, Talbott G, et al: Antibodies against CD14 protect primates from endotoxin-induced shock. J Clin Invest 1996; 98:1533-1538
12. Verbon A, Dekkers PEP, ten Hove T, et al: IC14, an anti-CD14 antibody, inhibits endotoxin-mediated symptoms and inflammatory responses in humans. J Immunol 2001; 166: 3599-3605
13. Reinhart K, Glück T, Ligtenberg J, et al: CD14 receptor occupancy in severe sepsis: Results of a phase I clinical trial with recombinant chimeric CD14 monoclonal antibody (IC14). Crit Care Med 2004; 32:1100-1108
14. Tamura Y, Higuchi Y, Kataoka M, et al: CD14 transgenic mice expressing membrane and soluble forms: Comparison of levels of cytokines and lethalities in response to lipopolysaccharide between transgenic and non-transgenic mice. Int Immunol 1999; 11: 333-339
15. Frevert CW, Matute-Bello G, Skerrett SJ, et al: Effect of CD14 blockade in rabbits with Escherichia coli pneumonia and sepsis. J Immunol 2000; 164:5439-5455